No batch too small: Choosing the right fill-finish CDMO for small-scale batches
This development is driven by the rise of personalized medicine, orphan drugs, and advanced biologics, each requiring highly flexible and…
All articles by Miranda Mclaren
Miranda Mclaren
-
-
Six key steps to successful technical transfers of high potent oral solid dose drugs
As the world of small molecule pharmaceuticals advances, the combination of high pharmacological activity with greater selectivity is delivering therapeutic…
-
CDMO insights podcast series: Our Experience is Your Strength | Episode #5 Sustainable packaging
The pharma sector contributes 5% of global GHG emissions1, a fact that has helped drive the top 46% of pharmaceutical…
-
PCI Pharma Services completes acquisition of Ajinomoto Althea
Philadelphia, PA – PCI Pharma Services (“PCI”) – a leading global contract development and manufacturing organization (CDMO) focused on innovative…
-
CDMO insights podcast series: Our Experience is Your Strength | Episode #4 Commercial Launch
Once a drug receives regulatory approval, the clock starts ticking to get high-quality products packed, shipped, and available on the…
-
Top seven considerations when selecting primary packaging for injectable drugs
Between the start of 2022 and the end of 2024, GlobalData’s Drugs database recorded 160 US approvals for currently marketed…
-
CDMO insights podcast series: Our Experience is Your Strength | Episode #3 Clinical Forecasting, Packaging & Distribution
In the high-stakes world of clinical trials, timing is everything, but that doesn’t mean faster is always better. In the…
-
Meet the company on a mission to rewrite the cell therapy paradigm from South Texas
While major hurdles are still to be overcome, cell therapies have finally become a reality for certain cancers, and soon…
-
Exploring AI-powered cell simulations and the launch of the world’s first virtual lab
Artificial intelligence and machine learning (AI/ML) are fundamentally changing the world of drug discovery, enabling researchers to identify the potential…
-
Five considerations when scaling up mAbs in partnership with a CDMO
Scaling up production is a key stage in the lifetime of a monoclonal antibody (mAb), fraught with the risk of…